Allergy/Asthma News

As peak asthma month begins, school resumes, and the season for environmental allergens and viruses kicks off, allergists can expect to treat more patients.

In a Healio Expert Submission, Douglas H. Jones, MD, FAAAAI, FACAAI, discussed currently available food allergy treatments and some that are in development.

As fall draws near, so does the season for viruses and environmental allergens, which can trigger asthma. Experts say that with children returning to school and the season changing, allergists can expect to see an increase in patients.

Patients infected with SARS-CoV-2 had altered growth patterns in their blood and showed signs of reduced immune cells 10 months after infection, according to a study published in Allergy.

Nearly half of parents are worried about their child developing a hereditary health condition, according to results from the C.S. Mott Children’s Hospital National Poll of Children’s Health.

To overcome barriers to biologic care for patients with asthma, personalized treatment is key, according to a speaker at the 16th Annual Allergy, Asthma & Immunology CME Conference.

The FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray for emergency allergic reactions in children and adults weighing at least 66 pounds.

Medicine was an interesting thought as I was growing up with no medical people in my family.

The FDA has approved Palforzia, an oral immunotherapy designed to protect children aged 1 to 3 years with peanut allergies from reactions caused by accidental exposure, according to a press release.